Reacta Healthcare aims to improve the quality of life for severe food allergy sufferers globally through accurate diagnosis and therapeutic monitoring.

Reacta is addressing an unmet need for standardised Challenge Meals which are used in clinical trials as Oral Food Challenges (OFCs). OFCs are the gold standard for food allergy diagnosis. With leading scientific and clinical experts in food allergy, the business developed an innovative and easy to use Challenge Meal. The Reacta Challenge Meals delivers specific doses of a fully masked allergen including a non-allergen formulation that is indistinguishable in taste and texture from the allergen containing formulation.

The Reacta Peanut Challenge Meal is currently in use by clinicians as part of numerous clinical trials worldwide with Milk and Egg Challenge Meals being launched in early 2023. Products are manufactured in a world-class 'Pharma GMP' facility in North Wales. The site includes a purpose-built new product development allergy suite and additional analytical laboratories will follow in 2023. Reacta Healthcare has recently secured a patent in USA, supplementing the patents already held across Europe, Australia, Canada, Hong Kong and UK. 

The company has grown its employees from 10 to 40 in the last year. In June 2021 Reacta closed the largest funding round for Reacta since inception with Praetura Ventures joined the existing investors which include the Development Bank of Wales and Perscitus Capital LLP.

https://www.reactahealthcare.com/2022/08/08/reacta-healthcare-secures-first-us-patent/